Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — FY2022 Earnings Presentation
11 slides from Xbrane Biopharma AB's earnings presentation, Feb 17, 2023
Slide 1: Xbrane Biopharma Year-end Report 2022
Xbrane Biopharma Year-end Report 2022 "EMA’s approval of Ximluci® positions Xbrane as a leading Biosimilar Developer’ Martin Amark, CEO Solna February 17", 2023 *) European Medicines Agency
Slide 2: Disclaimer
Disclaimer ‘You must read the following before continuing, The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company” or any person on behalf of the Company and any other material distributed or statements made in connection
Slide 3: Xbrane has a portfolio addressing €53 billion of peak reference product sales
Xbrane has a portfolio addressing €53 billion of peak reference product sales Reference Product Patent | Peak sales| Development Commercialization lnsliceattar Expiry | estimate* Phase Next milestone Partner Candidate Q1:2023 Submission Age-related macular of BLA _ ~ degeneration 2020/22 Q1 2023: La
Slide 4: Europe – a €4 bn market opportunity, STADA well-armed for Ximluci launch
Europe – a €4 bn market opportunity STADA well-armed for a successful launch Ximluci® overview → Dedicated biosimilars team within STADA Global Equivalent to Lucentis® Europe retinal VEGF inhibitor market € million (dosing, administration, safety, Specialty Care efficacy, PK, immunogenicity) 5000 →
Slide 5: Upcoming Capital Market Days 2023
Upcoming Capital Market Days 2023 REDEYE * Redeye "Swedish Success Day” Feb 215, 2023 peseasoe> + Aktiespararna March 13", 2023 . * BioStock Investor Meeting March 16'", 2023 Aktiespararna * Kempen Capital Markets Day April, 2023 * ABG Life Science Summit May 318!, 2023 Healthcare Conference XBRANE
Slide 6: Ambition to be the most attractive Employer within our field
Ambition to be the most attractive Employer within our field Certified as a Great Place to Work® Equality Management team 61% vs 39% 50/50 No of employees +36% YoY 90 79 80 a 74 70 64 58 mWomen ™Men mWomen ™Men 60 50 International 45 Experience 40 43% vs 57% 40 34% PhD's 30 35 20 30 10 25 ) Q4'21 Q1
Slide 7: Year-end Report 2022 Financials
Slide 8: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q4'21 Qi '22 Q2 122 Q3 '22 Q4 '22 Total Company Expenses expensed in the P&L have 0 increased by +35mSEK, with a number of factors contributing -10 20 1. Ximluci® moves from a development phase into a commercial phase, hence majority of costs do not -30 longer justify
Slide 9: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q4'21 Qi '22 Q2 '22 Q3 '22 Q4 '22 Comparing “like-for-like” year-on-year, the total Operating Costs have 0 increased by 44,8% -10 -20 28,9 -30 -40 -50 _ -60 -70 -90 44.8% A total of SEK 102m is now capitalized on the Balance Sheet related G&A R&D mlntangible assets to
Slide 10: Cash and Cash Equivalents, Shareholders' Equity
Cash and Cash Equivalents Shareholders’ Equity 350 500 295,2 301,5 450 —431,7 424.9 300 396,3 250,1 400 365,7 250 350 326,8 200 194 300 165,2 250 150 550) 100 150 sp 100 50 0 0 Q4'21 1122, 222,322, 4 122 a4'24 Qt'22, 222, 322, 4 122 At the end of the fourth quarter 2022, Cash amounted to 194.0 MSEK.
Slide 11: Q&A